| 摘要 |
A new group of compounds (I) having muscarinic activity is disclosed, wherein m is 0 or 1; p is 1 or 2; X is C(R)2, O, S(O)q, NR, C(=O), CHOR, C=NOR, NC(=O)OR, NC(=O)N(R)2, NC(=O)R, CHC(=O)OR, CHC(=O)N(R)2, CHC(=O)R, NS(O)2C(R)3, (a) or (b); R<1> and R<2> are independently H, lower alkyl, halogen, lower alkoxyl, OH, HOCH, aryl, arylalkyl, SR or N(R)2, and A is selected from the group consisting of: (c), (d) and (e) wherein <o>----</o> represents a double or single bond; n is 0 or 1; o is 1 or 2; R<3> is H, lower alkyl, halogen, lower alkoxyl, OH, HOCH2, aryl, arylalkyl, SR or N(R)2; and B is selected from the group consisting of (f), (g), (h), (i), (j), (k) or CO2R. The use of the compounds and pharmaceutically acceptable salts thereof to treat glaucoma, myopia, psychosis and various other conditions involving muscarinic receptors is also disclosed. |
